Palatin Technologies Inc

Palatin Technologies Inc. a biopharmaceutical company develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177 a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition the company engages in the development of PL9643 a peptide melanocortin agonist active at multiple MCrs including MC1r and MC5r for anti-inflammatory ocular indications such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further it is developing PL3994 a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177 an oral peptide formulation for treatment of ulcerative colitis which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury New Jersey.